PMID- 24836432
OWN - NLM
STAT- MEDLINE
DCOM- 20150528
LR  - 20220331
IS  - 2042-7670 (Electronic)
IS  - 0042-4900 (Linking)
VI  - 175
IP  - 10
DP  - 2014 Sep 13
TI  - Phenobarbitone-induced haematological abnormalities in idiopathic epileptic dogs: 
      prevalence, risk factors, clinical presentation and outcome.
PG  - 247
LID - 10.1136/vr.102158 [doi]
AB  - The aim of this retrospective study was to assess prevalence, risk factors, 
      clinical presentation and outcome of phenobarbitone induced haematological 
      abnormalities (PBIHA) in dogs. The medical records of two veterinary referral 
      institutions were searched for dogs diagnosed with idiopathic epilepsy and 
      treated with PB as monotherapy or polytherapy between March 2003 and September 
      2010. Sixteen dogs had PBIHA; the median age at diagnosis was 69.5 months. 
      Phenobarbitone was administered at a median dose of 3 mg/kg twice a day for a 
      median period of 100.5 days and the median serum phenobarbitone level was 
      19 mug/ml. Two dogs had neutropenia, three had anaemia and thrombocytopenia, two 
      had anaemia and neutropenia; the remaining nine had pancytopenia. All dogs were 
      referred for non-specific clinical signs. Phenobarbitone was discontinued after 
      diagnosis, and the median time to resolution of PBIHA was 17 days. The prevalence 
      and risk factors for PBIHA were evaluated from a questionnaire survey of 
      referring practices to obtain more detailed follow-up on cases diagnosed with 
      idiopathic epilepsy. The prevalence rate of PBIHA was 4.2%, and the condition 
      occurred in dogs treated with standard therapeutic doses often within the first 
      three months after starting treatment. Serial haematological evaluations should 
      be therefore considered from the beginning of phenobarbitone therapy to allow 
      early diagnosis and treatment of PBIHA.
CI  - British Veterinary Association.
FAU - Bersan, E
AU  - Bersan E
AD  - Department of Veterinary Science, Small Animal Teaching Hospital, University of 
      Liverpool, Wirral, UK Animal Health Trust, Lanwades Park, Kentford, Newmarket, 
      UK.
FAU - Volk, H A
AU  - Volk HA
AD  - Department of Clinical Science and Services, Royal Veterinary College, University 
      of London, London, UK.
FAU - Ros, C
AU  - Ros C
AD  - Animal Health Trust, Lanwades Park, Kentford, Newmarket, UK.
FAU - De Risio, L
AU  - De Risio L
AD  - Animal Health Trust, Lanwades Park, Kentford, Newmarket, UK.
LA  - eng
PT  - Journal Article
DEP - 20140516
PL  - England
TA  - Vet Rec
JT  - The Veterinary record
JID - 0031164
RN  - 0 (Anticonvulsants)
RN  - YQE403BP4D (Phenobarbital)
SB  - IM
CIN - Vet Rec. 2014 Sep 13;175(10):245-6. PMID: 25217601
MH  - Animals
MH  - Anticonvulsants/*adverse effects
MH  - Dog Diseases/chemically induced/*drug therapy/epidemiology
MH  - Dogs
MH  - Epilepsy/drug therapy/*veterinary
MH  - Female
MH  - Hematologic Diseases/chemically induced/epidemiology/*veterinary
MH  - Male
MH  - Phenobarbital/*adverse effects
MH  - Prevalence
MH  - Records
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Treatment Outcome
MH  - Veterinary Medicine
EDAT- 2014/05/20 06:00
MHDA- 2015/05/29 06:00
CRDT- 2014/05/20 06:00
PHST- 2014/05/20 06:00 [entrez]
PHST- 2014/05/20 06:00 [pubmed]
PHST- 2015/05/29 06:00 [medline]
AID - vr.102158 [pii]
AID - 10.1136/vr.102158 [doi]
PST - ppublish
SO  - Vet Rec. 2014 Sep 13;175(10):247. doi: 10.1136/vr.102158. Epub 2014 May 16.